Evidence map›Paper›PMID 40213484›Full record

ArticleSmall science2024

Overcoming the Blood-Brain Barrier: Multifunctional Nanomaterial-Based Strategies for Targeted Drug Delivery in Neurological Disorders.

Callan D McLoughlin, Sarah Nevins, Joshua B Stein, Mehrdad Khakbiz, Ki-Bum Lee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Small science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Callan D McLoughlinDepartment of Chemistry and Chemical Biology Rutgers, The State University of New Jersey 123 Bevier Road Piscataway NJ 08854 USA.
Sarah NevinsDepartment of Chemistry and Chemical Biology Rutgers, The State University of New Jersey 123 Bevier Road Piscataway NJ 08854 USA.
Joshua B SteinDepartment of Chemistry and Chemical Biology Rutgers, The State University of New Jersey 123 Bevier Road Piscataway NJ 08854 USA.
Mehrdad KhakbizDepartment of Chemistry and Chemical Biology Rutgers, The State University of New Jersey 123 Bevier Road Piscataway NJ 08854 USA.
Ki-Bum LeeDepartment of Chemistry and Chemical Biology Rutgers, The State University of New Jersey 123 Bevier Road Piscataway NJ 08854 USA.ORCID https://orcid.org/0000-0002-8164-0047

Funding

Rutgers Biotechnology Training ProgramT32GM135141 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · PI ANN M. STOCK, Martin L Yarmush · 2020 to 2026
$3.5M
NIGMS NIH HHS T32 GM135141
6 · The paper itself

Abstract

The development of effective therapies for neurological disorders is a growing area of research due to the increasing prevalence of these conditions. Some neurological disorders that are prevalent and remain difficult to treat are glioma, neurodegenerative disease, ischemic stroke, and traumatic brain injury. Subsequently, the therapeutic efficacy of small molecules, proteins, and oligonucleotides remains a challenge due to the presence of the blood-brain barrier (BBB), a highly selective semipermeable membrane. To this end, multifunctional nanomaterials have emerged as promising vehicles for targeted drug delivery to the brain, due to their ability to transport therapeutics across the BBB selectively. The design of advanced nanomaterial-based drug delivery systems capable of overcoming the BBB is influenced by many factors, such as fabrication technique and surface modification. This review explores the diverse range of nanomaterials, including polymer, lipid, gold, magnetic, and carbon-based nanostructures, capable of effectively passing the BBB. These materials cross the BBB via a variety of established transport mechanisms for targeted delivery of therapeutics to the brain. Moreover, the structure and function of the BBB are highlighted and the potential for nanotechnology to aid the treatment of neurological disorders based on their ability to undergo transcytosis into the brain is highlighted.

Indexed as

blood–brain barriersgliomamultifunctional nanoparticlesnanoparticle‐based drug delivery systemsneurodegenerative diseasesneurological disorderstargeted drug deliveries

Identifiers

PMID40213484
PMCPMC11935220

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.